U.S. Specialized REITs Stock News

In March 2026, Bristol Myers Squibb reported expanded approvals for Opdivo in classical Hodgkin lymphoma and unveiled new clinical and real-world data for Camzyos in obstructive hypertrophic cardiomyopathy, including the successful Phase 3 SCOUT-HCM trial in adolescents. Together, these updates reinforce Bristol Myers Squibb’s position in oncology and cardiovascular care by broadening Opdivo’s treatment reach and deepening the evidence base behind Camzyos across a range of real-world and...

CrowdStrike Holdings (CRWD) has been busy, rolling out a series of AI focused security updates and partnerships with IBM and Intel that tighten integration across SOC automation, AI PCs, data protection, and agent based defenses. See our latest analysis for CrowdStrike Holdings. Despite the flurry of AI focused launches and partnerships, CrowdStrike’s recent share price moves have been mixed. The stock has delivered a 10.14% 1 month share price return alongside a 19.13% 3 month share price...

Wondering if Merck at around US$119 per share still offers value, or if most of the upside is already reflected in the price? This article walks through the key data points that matter for you. Merck’s share price sits near US$119.37, with returns of 4.3% over 7 days, a 3.6% decline over 30 days, 12.1% year to date and 40.4% over the past year. This raises fair questions about both growth potential and how risk is being priced in. Recent news coverage around Merck has focused on its position...

Regulators are preparing to ease bank capital requirements, reducing the amount of capital some banks may need to hold against their assets. Moody's has flagged these planned changes as credit negative, signaling concern about higher credit risk for financial institutions. The shift in regulatory stance could influence how Moody's assesses bank balance sheets and assigns credit ratings across the sector. Moody's, traded as NYSE:MCO, sits at the center of global credit assessment, so any...

If you are wondering whether Commerce Bancshares at around US$48.54 is starting to look like value, or still has more room to fall or recover, this article will walk you through what the current price might be implying. The stock has gained 2.2% over the last 7 days, although it remains 7.1% lower over the past month and 17.1% lower over the last year. This may have some investors reassessing both its potential and its risks. Recent attention on the broader US banking sector, shifts in...

If you are wondering whether MetLife's current share price reflects its underlying worth, the recent moves in the stock give you plenty to think about. The shares last closed at US$70.39, with a 2.6% gain over the past week, a 6.4% decline over 30 days, and returns of 12.4% decline year to date and 13.6% decline over the last year, set against gains of 36.7% and 34.8% over 3 and 5 years respectively. Recent headlines around MetLife have focused on the business as a large US insurer,...

Cadence Design Systems (NasdaqGS:CDNS) has appointed Dr. Alok Jain as Managing Director for India. The appointment positions India as a key innovation and R&D hub for the company’s semiconductor and design software efforts. Dr. Jain is expected to focus on relationships across government, academia, and industry within India’s growing chip ecosystem. Cadence Design Systems, a major player in electronic design automation and semiconductor IP, is putting more executive weight behind India as a...

If you are wondering whether Chemed at around US$374 per share still reflects its underlying worth, the current valuation picture offers some clear signals to work through. The share price has pulled back recently, with a 2.4% decline over the past week, a 21.8% drop over the last 30 days, and a 38.3% decline over the past year. This may have shifted how investors see both risk and potential reward. Recent coverage has focused on Chemed's role in healthcare services and how sector wide...

At its March 24, 2025 AGM, Coca-Cola FEMSA, S.A.B. de C.V. approved a cash dividend of MXN 0.9675 per share (MXN 7.74 per KOF UBL unit) for fiscal 2025, to be paid in four equal installments during April, July, October, and December 2026. This multi‑installment dividend, spreading payments across the year, gives investors greater visibility on expected cash returns and may influence how they assess the company’s capital allocation and income profile. We’ll now examine how this AGM-approved,...

Earlier this week, PPG Industries introduced PPG InsightsNav, a global analytics platform that helps marine customers standardize and analyze seastock coatings purchasing data, while also reaffirming a commitment to invest US$10.00 million through 2030 in skilled trades programs tied to advanced manufacturing and coatings applications. Together, the digital InsightsNav offering and long-term skilled trades funding highlight how PPG is pairing data-driven tools with workforce development to...

Earlier this month, Cheniere Energy closed a private offering of US$1.00 billion of 5.200% Senior Notes due 2036 and US$750.00 million of 6.000% Senior Notes due 2056, issued just below par under an indenture with The Bank of New York Mellon and carrying customary covenants and optional redemption features. The unregistered Rule 144A and Regulation S issuance adds long-dated, senior unsecured debt that Cheniere can later exchange into registered securities, potentially broadening its...

HP (NYSE:HPQ) has introduced HP NearSense, a new cross-device experience built with Google and Qualcomm for secure workflows across HP PCs, Android devices, and multiple workspaces. The company is expanding its local AI layer, HP IQ, across devices to support on-device, context-aware productivity features. HP also announced TPM Guard hardware to counter advanced physical attacks on business PCs and quantum-resistant security for its printer portfolio. For investors tracking NYSE:HPQ, these...

Earlier this month, SentinelOne announced it is expanding its partnership with Cloudflare to feed Cloudflare’s Zero Trust and edge security telemetry directly into SentinelOne’s Singularity AI SIEM, creating a unified, AI-driven threat detection and response experience for joint enterprise customers. This deeper integration positions Cloudflare’s network and security data as a core ingredient in AI-powered security operations, potentially enhancing its relevance in the shift toward...

On March 18, 2026, ScottsMiracle-Gro, Bonnie Plants and Gardenuity launched the Inspired to Gro Patio Garden Collection, bundling plant nutrients, rooted starter plants and guided digital support into a single patio-gardening product now sold on Amazon, Bonnieplants.com and Gardenuity.com. The collaboration stands out by pairing physical gardening inputs with Gardenuity’s personalized coaching and weather-based alerts, aiming to remove common barriers that keep new gardeners from starting...

Ocugen (OCGN) has attracted fresh attention after recent trading left the shares at US$1.95, against a market value of about US$648.8m. This has prompted investors to reassess how its pipeline and financials line up. See our latest analysis for Ocugen. Recent trading has been choppy, with a 1-day share price return of 1.56% set against a 7-day share price return decline of 14.85%. However, the 90-day share price return of 35.42% and 1-year total shareholder return of 163.87% point to momentum...

Wondering if Moderna at US$53.54 is a bargain or a value trap? This article walks through what the numbers are really saying about the stock. The share price return sits at 2.2% over 7 days, 6.5% over 30 days, 73.5% year to date and 70.1% over the last year, alongside a 64.0% decline over 3 years and a 59.1% decline over 5 years. Recent headlines around Moderna have focused on its position in the pharmaceutical and biotech space and how investors are reassessing companies in this part of the...

In March 2026, Uranium Energy Corp. reported state approvals and startup of three new header houses at Christensen Ranch in Wyoming, alongside an NRC docket for its planned U.S. uranium conversion facility, advancing both production capacity and licensing progress for refining and conversion. These steps move the company closer to its goal of becoming a fully vertically integrated American nuclear fuel supplier, potentially enhancing control over the domestic fuel chain and mitigating...

Event driven move in Paymentus Holdings (PAY) Paymentus Holdings (PAY) is back on investor radars after recent trading activity highlighted a mixed return profile, with gains over the past month set against a roughly 21% decline over the past 3 months. See our latest analysis for Paymentus Holdings. At a share price of US$25.10, Paymentus sits between a modest 30 day share price return and a much weaker 90 day share price return, while the 3 year total shareholder return above 100% points to...

Investor activism meets softer quarterly results AutoNation (AN) is facing closer investor scrutiny after a softer Q4, with revenue down 3.9% year on year and earnings missing analyst estimates, even as After-Sales and Customer Financial Services reported record gross profit. See our latest analysis for AutoNation. AutoNation's share price has softened recently, with a 30 day share price return of 1.64% decline and a 90 day share price return of 8.82% decline, even as the 1 year total...

Wondering if Oncolytics Biotech at around US$0.95 is offering value or just extra risk? This article breaks down what that price tag could really mean for you. The stock is roughly flat year to date with a 3.4% decline. It has returned 54.7% over the last year, which can raise questions about how much potential or risk might already be reflected in the price. Recent coverage has focused on Oncolytics Biotech's progress as a clinical stage cancer therapy developer and the implications of its...

Valero Energy (NYSE:VLO) is facing a worker lawsuit that alleges negligence after the recent explosion at its Port Arthur refinery. The suit claims gross negligence related to safety practices and working conditions at one of Valero's largest facilities. This legal action adds fresh scrutiny to the company's operational risk management and potential liability exposure. Valero is one of the largest independent refiners in the US, with operations that supply transportation fuels and other...

IDEAYA Biosciences recently updated investors on the timing of topline data from its Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma, indicating that the database lock occurred in the first half of April and that a live webcast will follow to discuss the results. This combination of a clarified data-readout timeline and a planned investor-and-expert webcast highlights how the trial’s outcome could meaningfully shape perceptions of IDEAYA’s clinical...

Maze Therapeutics reported promising Phase II results for its APOL1-mediated kidney disease candidate MZE829. The company plans to move MZE829 into pivotal testing, targeting the same indication as Vertex Pharmaceuticals' inaxaplin program. This development introduces a new competitor to NasdaqGS:VRTX in the APOL1-mediated kidney disease space. Vertex Pharmaceuticals, listed as NasdaqGS:VRTX, is known for its focus on serious diseases with high unmet need, and inaxaplin is one of its key...

Worthington Enterprises (WOR) has reported a busy quarter, with Q3 2026 revenue at US$378.7 million and basic EPS of US$0.93, alongside trailing 12 month EPS of US$2.27 that sits against reported earnings growth of 84.3% over the past year and a longer term 5 year earnings decline of 47.8% per year. Over recent quarters the company has seen revenue move from US$274.0 million in Q2 2025 to US$304.5 million in Q3 2025 and then to US$378.7 million in Q3 2026. Quarterly basic EPS shifted from...